<?xml version="1.0" encoding="UTF-8"?>
<ref id="B129-pharmaceutics-13-00387">
 <label>129.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Alayoubi</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Daihom</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Adhikari</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Mishra</surname>
    <given-names>S.R.</given-names>
   </name>
   <name>
    <surname>Helms</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Almoazen</surname>
    <given-names>H.</given-names>
   </name>
  </person-group>
  <article-title>Development of a taste-masked oral suspension of clindamycin HCl using ion exchange resin Amberlite IRP 69 for use in pediatrics</article-title>
  <source>Drug Dev. Ind. Pharm.</source>
  <year>2016</year>
  <volume>42</volume>
  <fpage>1579</fpage>
  <lpage>1589</lpage>
  <pub-id pub-id-type="doi">10.3109/03639045.2016.1160102</pub-id>
  <?supplied-pmid 26926148?>
  <pub-id pub-id-type="pmid">26926148</pub-id>
 </element-citation>
</ref>
